Medtronic shares: Positive trend despite challenges ()

The Medtronic share recorded a slight increase of 0.03% to USD 89.45 (as of September 27, 2024). Despite ongoing challenges in the medical technology industry, the company remains resilient. The latest quarterly results exceeded analysts’ expectations, indicating robust demand for Medtronics’ innovative products. The areas of cardiology and diabetes management developed particularly strongly.

The outlook remains cautiously optimistic

For the coming fiscal year, Medtronic forecasts sales growth of 3-4%. However, ongoing supply chain problems and strong competitive pressure remain risk factors. Investors value the stable dividend yield of 3.32% and the potential for further growth through investments in new technologies. The next few months will show whether Medtronic can continue its growth path.

Advertisement

Medtronic shares: buy or sell?! New Medtronic analysis from September 27 provides the answer:

The latest Medtronic figures speak for themselves: there is an urgent need for action for Medtronic shareholders. Is it worth getting started or should you sell? In the current free analysis from September 27th you will find out what to do now.

Medtronic: Buy or Sell? Read more here…